Massachusetts-based Catalog, which claims to be developing a DNA-based computing platform, raises $35M Series B, bringing total funding to $45M+
The Transform Technology Summits start October 13th with Low-Code/No Code: Enabling Enterprise Agility. Register now!
Context & Ripple Effects
Catalog has been working toward this round since it emerged from Harvard's Life Lab in 2018 with $9M to commercialize its DNA-based data storage method. The new $35M Series B takes it past $45M raised — a three-year gap between rounds that suggests the company spent the interim proving the biology before scaling the pitch.
The raise lands in a September–October window where venture money is flowing heavily into unconventional data infrastructure, from Materialize's SQL database for streaming data to Tonic.ai's $45M synthetic-data bet.
First-order effects
- Catalog now has the capital to move DNA storage from lab demonstration toward a commercializable product, executing on the roadmap it laid out at its 2018 emergence.
- Its investors are underwriting an unproven medium against a backdrop where comparable data-infrastructure rounds (Materialize at $100M+ total, StrongDM at $77M) show buyers of risk expect far larger totals.
Second-order effects
- Catalog competes for the same data-infrastructure allocation as the streaming-database and synthetic-data plays funded the same week, so every dollar into DNA storage pressures VCs to pick between exotic media and incremental software layers.
- If Catalog shows write/read economics improving, archival-heavy customers gain a second sourcing option beyond incumbent storage vendors, forcing those vendors to defend their roadmaps.
Third-order effects
- Should DNA-based storage keep attracting institutional capital, archival data becomes a contested layer rather than settled territory — with the caveat that no customer deployments or revenue figures appear in the coverage, so commercial traction remains unverified.
- A sustained pattern of deep-science infrastructure rounds would push later-stage funds to build biotech-compute diligence capability they historically lacked.
The trend: Venture capital is broadening beyond conventional data software into alternative physical substrates for storing and computing on data.